AIM ImmunoTech Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $88,000 | $170,000 | $202,000 | $141,000 | $135,000 |
| Research and development | $3.9M | $6.2M | $10.9M | $7.0M | $7.7M |
| Operating income | -$11.7M | -$19.8M | -$31.9M | -$19.9M | -$18.8M |
| Interest expense | $812,000 | $585,000 | — | — | $67,000 |
| Pretax income | -$14.0M | — | — | — | — |
| Net income | -$14.0M | -$17.3M | -$29.0M | -$19.4M | -$19.1M |
| Balance Sheet | |||||
| Cash and equivalents | $3.0M | $1.7M | $5.4M | $27.1M | $32.1M |
| Current assets | $3.3M | $4.2M | $14.6M | $36.3M | $50.2M |
| Total assets | $5.8M | $8.6M | $19.4M | $40.5M | $57.7M |
| Current liabilities | $6.2M | $9.5M | $8.7M | $1.4M | $673,000 |
| Total liabilities | $15.6M | $9.9M | $9.1M | $2.0M | — |
| Total debt | $5.3M | $2.8M | — | — | — |
| Stockholders' equity | -$9.8M | -$1.3M | $10.2M | $38.5M | $56.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$11.0M | -$14.9M | -$21.3M | -$16.1M | -$14.0M |
| Depreciation and amortization | $37,000 | $37,000 | $39,000 | $38,000 | $659,000 |
| Stock-based compensation | $60,000 | $686,000 | $243,000 | $954,000 | $1.6M |
| Capital expenditure | — | $18,000 | — | $86,000 | $41,000 |
| Free cash flow | — | -$14.9M | — | -$16.2M | -$14.0M |
| Impairments | $1.1M | $48,000 | — | — | $1.8M |
Shares outstanding 14.6M · Free float 75.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.